MarketCap
Facebook
X
Telegram
CareDx, Inc Book Value | CDNA
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value CareDx, Inc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 303 M | 378 M | 261 M | 431 M | 466 M | 278 M | 99 M | 95.9 M | -5.95 M | 19.8 M | 29.5 M | 41.3 M | -151 M | -147 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 466 M | -151 M | 150 M |
Quarterly Book Value CareDx, Inc
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 467 M | 426 M | 314 M | 303 M | 311 M | 327 M | 379 M | 378 M | 273 M | 265 M | 256 M | 261 M | 394 M | 405 M | 420 M | 431 M | 437 M | 444 M | 458 M | 466 M | 472 M | 480 M | 472 M | 278 M | 269 M | 261 M | 101 M | 99 M | 97.5 M | 93.2 M | 95.6 M | 95.9 M | 44.4 M | 29 M | 33.4 M | -5.95 M | -175 K | 12 M | 14.9 M | 19.8 M | 36.8 M | 32.5 M | 20.5 M | 29.5 M | 33.9 M | 36.8 M | 39.5 M | 41.3 M | 41 M | 41.3 M | 41.3 M | -15.5 M | -15.5 M | -15.5 M | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 480 M | -15.5 M | 199 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B |  USA |
 |
DarioHealth Corp.
DRIO
|
110 M | $ 2.4 | -11.93 % | $ 9.56 M |  Israel |
 |
Myriad Genetics
MYGN
|
368 M | $ 5.97 | -5.17 % | $ 553 M | USA |
 |
ENDRA Life Sciences
NDRA
|
2.26 M | $ 4.73 | -5.49 % | $ 3.72 M | USA |
 |
NeoGenomics
NEO
|
837 M | $ 16.85 | 2.18 % | $ 2.16 B | USA |
 |
OPKO Health
OPK
|
1.27 B | $ 1.72 | -1.71 % | $ 1.29 B | USA |
 |
Pacific Biosciences of California
PACB
|
5.35 M | $ 2.3 | -5.35 % | $ 690 M | USA |
 |
Neogen Corporation
NEOG
|
2.09 B | $ 11.75 | 0.6 % | $ 2.56 B | USA |
 |
Precipio
PRPO
|
14.6 M | $ 18.95 | 2.02 % | $ 30.4 M | USA |
 |
Personalis
PSNL
|
261 M | $ 15.76 | 1.32 % | $ 1.41 B | USA |
 |
Sotera Health Company
SHC
|
606 M | $ 16.01 | 0.88 % | $ 4.55 B | USA |
 |
Quidel Corporation
QDEL
|
11.9 B | $ 10.69 | -16.78 % | $ 450 M | USA |
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
1.83 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | USA |
 |
Check-Cap Ltd.
CHEK
|
7.49 M | - | - | $ 9.42 M | Israel |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
14 M | $ 25.62 | 0.55 % | $ 573 M | USA |
 |
Twist Bioscience Corporation
TWST
|
473 M | $ 120.83 | 0.18 % | $ 7.23 B | USA |
 |
Organovo Holdings
ONVO
|
-1.1 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
31.9 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
7.25 B | - | -0.91 % | $ 14.7 B | USA |
 |
Soleno Therapeutics
SLNO
|
450 M | - | - | $ 2.69 B | USA |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 257.93 | 1.18 % | $ 28.6 B | USA |
 |
Danaher Corporation
DHR
|
83.5 B | $ 230.45 | 1.76 % | $ 164 B | USA |
 |
IDEXX Laboratories
IDXX
|
1.61 B | $ 676.3 | 0.83 % | $ 54.4 B | USA |
 |
Illumina
ILMN
|
6.64 B | $ 213.05 | 2.43 % | $ 33 B | USA |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 100.61 | -0.09 % | $ 6.79 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-56 M | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
459 M | $ 653.24 | 2.88 % | $ 18.8 B | USA |
 |
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 722.36 | 2.64 % | $ 35.5 B |  Schweiz |
 |
Natera
NTRA
|
1.71 B | $ 319.38 | -12.2 % | $ 43.7 B | USA |
 |
Charles River Laboratories International
CRL
|
3.21 B | $ 338.13 | 8.07 % | $ 16.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
11 B | $ 30.33 | -0.57 % | $ 28.8 B |  Niderland |
 |
QIAGEN N.V.
QGEN
|
6.28 B | $ 50.36 | -0.98 % | $ 10.9 B | Niderland |
 |
RadNet
RDNT
|
1.36 B | $ 75.83 | -2.79 % | $ 5.7 B | USA |
 |
Senseonics Holdings
SENS
|
61 M | $ 8.58 | 7.38 % | $ 358 M | USA |
 |
T2 Biosystems
TTOO
|
-28 M | - | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
26.2 M | $ 2.17 | -10.91 % | $ 143 M | USA |
 |
Thermo Fisher Scientific
TMO
|
110 B | $ 694.85 | 2.62 % | $ 262 B | USA |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Trinity Biotech plc
TRIB
|
-35.2 M | $ 6.07 | 2.97 % | $ 2.18 B |  Irlanda |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 11.12 | 4.81 % | $ 378 M | Israel |
 |
VolitionRx Limited
VNRX
|
-35.6 M | $ 0.2 | 3.39 % | $ 25.2 M |  Singapore |
 |
Waters Corporation
WAT
|
2.56 B | $ 458.04 | 1.06 % | $ 27.3 B | USA |
 |
Exagen
XGN
|
17.4 M | $ 5.79 | -23.82 % | $ 125 M | USA |